Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir
- PMID: 27621592
- PMCID: PMC5010074
- DOI: 10.2147/DDDT.S112852
Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir
Abstract
Background: This paper reports the results of a clinical study that tested the effect of suppressive treatment with the botanical product Gene-Eden-VIR/Novirin on the number of genital herpes outbreaks. The results in this study were compared to those published in clinical studies of acyclovir, valacyclovir, and famciclovir.
Methods: The framework was a retrospective chart review. The population included 139 participants. The treatment was one to four capsules of Gene-Eden-VIR/Novirin per day. The duration of treatment was 2-48 months. The study included three controls recommended by the US Food and Drug Administration (FDA): baseline, no treatment, and dose response.
Results: The treatment decreased the number of outbreaks per year in 90.8% of the participants. The treatment also decreased the mean number of outbreaks per year from 7.27 and 5.5 in the control groups to 2.39 (P<0.0001 and P<0.001, respectively). The treated participants reported no adverse experiences. Out of the 15 tests that compared Gene-Eden-VIR/Novirin to the three drugs, Gene-Eden-VIR/Novirin had superior efficacy in eight tests, inferior efficacy in three tests, and comparable efficacy in four tests. Gene-Eden-VIR/Novirin also had superior safety.
Conclusion: The clinical study showed that the natural Gene-Eden-VIR/Novirin decreases the number of genital herpes outbreaks without any side effects. The study also showed that the clinical effects reported in this study are mostly better than those reported in the reviewed studies of acyclovir, valacyclovir, and famciclovir.
Keywords: acyclovir; famciclovir; genital herpes; natural treatment; outbreaks; valacyclovir.
Figures

Similar articles
-
Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases.Clin Transl Med. 2016 Dec;5(1):40. doi: 10.1186/s40169-016-0121-6. Epub 2016 Oct 20. Clin Transl Med. 2016. PMID: 27766602 Free PMC article.
-
Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus.Drug Des Devel Ther. 2017 Mar 3;11:575-583. doi: 10.2147/DDDT.S123340. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28424535 Free PMC article.
-
Clinical Trial of Herbal Treatment Gene-Eden-VIR/Novirin in Oral Herpes.J Evid Based Integr Med. 2018 Jan-Dec;23:2515690X18806269. doi: 10.1177/2515690X18806269. J Evid Based Integr Med. 2018. PMID: 30362389 Free PMC article. Clinical Trial.
-
Genital herpes: antiviral therapy for symptom relief and prevention of transmission.Expert Opin Pharmacother. 2006 Apr;7(6):665-75. doi: 10.1517/14656566.7.6.665. Expert Opin Pharmacother. 2006. PMID: 16556084 Review.
-
Update on drugs for herpes zoster and genital herpes.Drug Ther Bull. 1998 Oct;36(10):77-9. doi: 10.1136/dtb.1998.361077. Drug Ther Bull. 1998. PMID: 10194872 Review. No abstract available.
Cited by
-
Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases.Clin Transl Med. 2016 Dec;5(1):40. doi: 10.1186/s40169-016-0121-6. Epub 2016 Oct 20. Clin Transl Med. 2016. PMID: 27766602 Free PMC article.
-
Anti-CMV therapy, what next? A systematic review.Front Microbiol. 2023 Nov 20;14:1321116. doi: 10.3389/fmicb.2023.1321116. eCollection 2023. Front Microbiol. 2023. PMID: 38053548 Free PMC article. Review.
-
Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus.Drug Des Devel Ther. 2017 Mar 3;11:575-583. doi: 10.2147/DDDT.S123340. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28424535 Free PMC article.
-
Flavonoids with Anti-Herpes Simplex Virus Properties: Deciphering Their Mechanisms in Disrupting the Viral Life Cycle.Viruses. 2023 Nov 29;15(12):2340. doi: 10.3390/v15122340. Viruses. 2023. PMID: 38140581 Free PMC article. Review.
-
Clinical Trial of Herbal Treatment Gene-Eden-VIR/Novirin in Oral Herpes.J Evid Based Integr Med. 2018 Jan-Dec;23:2515690X18806269. doi: 10.1177/2515690X18806269. J Evid Based Integr Med. 2018. PMID: 30362389 Free PMC article. Clinical Trial.
References
-
- Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370(9605):2127–2137. - PubMed
-
- Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983;98(6):958–972. - PubMed
-
- Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume JC, Lechat P, Chosidow O. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol. 2007;57(2):238–246. - PubMed
-
- Kukhanova MK, Korovina AN, Kochetkov SN. Human herpes simplex virus: life cycle and development of inhibitors. Biochemistry (Mosc) 2014;79(13):1635–1652. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical